Mannitol
Mannitol is a sugar alcohol (polyol) used as an osmotic diuretic.
- Pharmacologic class: Osmotic diuretic
- Does NOT cross intact BBB
- Freely filtered at glomerulus → not reabsorbed
Mechanism of Action
1. Intravascular Osmotic Effect
- Increases plasma osmolality
- Pulls water from:
- Brain parenchyma → ↓ cerebral edema
- Intraocular fluid → ↓ IOP
2. Renal Effect
- Filtered in glomerulus → remains in tubule
- Creates osmotic gradient → prevents water reabsorption
- → Osmotic diuresis
Effect on Brain
Phase-wise effects:
- Immediate (minutes)
- Plasma expansion → ↓ blood viscosity
- → Reflex cerebral vasoconstriction
- → ↓ cerebral blood volume → ↓ ICP
- Delayed (15–30 min)
- Osmotic gradient → water shifts from brain → plasma
- → ↓ brain bulk → ↓ ICP
- Rebound phenomenon
- Occurs if BBB disrupted
- Mannitol enters brain → reverses gradient
- → Worsening cerebral edema
Pharmacokinetics
|
Parameter |
Detail |
|
Onset |
5–10 min |
|
Peak |
20–60 min |
|
Duration |
4–6 hr |
|
Half-life |
~1.5–2 hr (↑ in renal failure) |
|
Excretion |
Renal (unchanged) |
Indications
Neurocritical Care
- Raised ICP:
- Traumatic brain injury
- Intracranial Hemorrhage
- Brain tumors
- Impending herniation (emergency bolus)
Ophthalmology
- Acute angle-closure glaucoma → ↓ IOP
Renal / ICU
- Prevention of AKI (controversial, NOT routine now)
- Rhabdomyolysis (selected cases)
Dose
Raised ICP
- 0.25–1 g/kg IV bolus
- Repeat based on ICP / osmolality
Target Monitoring:
- Serum osmolality: <320 mOsm/kg
- Osmolar gap: <55 mOsm/kg
Re-dosing
Instead of fixed timing:
Repeat 0.25–0.5 g/kg ONLY if:
- ICP still elevated (>20–22 mmHg)
- Clinical signs persist:
- Pupillary changes
- Low GCS
- CT worsening
Minimum interval
- Usually 4–6 hours
- BUT depends on:
- Serum osmolality
- Urine output
- Hemodynamics
Tapering strategy
- Increase dosing interval
- From 4 hourly → 6 hourly → 8 hourly
- Reduce dose
- From 1 g/kg → 0.5 g/kg → 0.25 g/kg
- Stop when:
- ICP stable
- Osmolality approaching 300–310
- Risk of AKI or hypovolemia
4. When to STOP immediately
- Serum osmolality >320 mOsm/kg
- Osmolar gap >55
- AKI / rising creatinine
- Hypotension / hypovolemia
- Pulmonary edema
Hemodynamic Effects
- Initial:
- Plasma expansion → ↑ preload
- May cause transient hypertension
- Later:
- Diuresis → ↓ intravascular volume
- Risk → hypotension
Adverse Effects
1. Volume-related
- Early: Fluid overload → pulmonary edema
- Late: Hypovolemia → hypotension
2. Electrolyte disturbances
- Hyponatremia (dilutional, early)
- Hypernatremia (late due to water loss)
- Hypokalemia / Hyperkalemia
3. Renal
- Osmotic nephrosis
- AKI (especially if repeated high doses)
4. CNS
- Rebound ICP ↑ (BBB disruption)
Contraindications
- Anuria / severe renal failure
- Pulmonary edema / CHF
- Active intracranial bleeding (relative; except perioperative neurosurgery)
- Severe dehydration
Monitoring
- Serum osmolality (keep <320)
- Urine output
- Electrolytes
- Renal function
- ICP (if available)
Mannitol vs Hypertonic Saline
|
Feature |
Mannitol |
Hypertonic Saline |
|
Mechanism |
Osmotic diuresis |
Osmotic + volume expansion |
|
Volume status |
Causes diuresis |
Expands intravascular volume |
|
BP |
May ↓ later |
Improves BP |
|
ICP effect |
Good |
Often superior |
|
Rebound ICP |
Possible |
Less common |
|
Use in shock |
Avoid |
Preferred |
Guidelines (Neurocritical Care Society / TBI guidelines):
- Both acceptable
- Hypertonic saline increasingly preferred, especially in hypotension
Clinical Pearls
- Mannitol works only if BBB intact
- Avoid repeated doses → risk of accumulation + rebound ICP
- If serum osmolality >320 → STOP
- Prefer hypertonic saline in:
- Hypotension
- Renal dysfunction
Special ICU Considerations
- Warm solution before use (crystallization common)
- Use inline filter
- Avoid in:
- ARDS
- Heart failure
